Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics Inc (ADMA)
:ADMA
ADMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.08 - $25.67
Previous CloseN/A
Volume407.39K
Average Volume (3M)3.29M
Market Cap
$4.92B
Enterprise ValueN/A
Total Cash (Recent Filing)$103.15M
Total Debt (Recent Filing)$82.12M
Price to Earnings (P/E)24.4
Beta1.05
Next Earnings
Aug 06, 2025EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding238,734,250
10 Day Avg. Volume1,933,463
30 Day Avg. Volume3,289,883
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)13.44
Price to Sales (P/S)0.00
P/FCF Ratio42.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.67Price Target Upside48.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ADMA Biologics News
PremiumCompany Announcements
ADMA Biologics Holds Annual Stockholders Meeting
PremiumCompany Announcements
ADMA Biologics Reports Strong Growth and Strategic Advances
PremiumCompany Announcements
ADMA Biologics Reports Strong Q1 2025 Financial Growth
PremiumCompany Announcements
ADMA Biologics Announces $500M Share Repurchase Program
Bulls Say, Bears Say
Bulls Say
EarningsADMA Biologics Inc has raised its 2025-2026 revenue guidance, indicating strong growth expectations.
ProductionThe anticipated approval of Ig yield enhancement is expected to significantly increase production output, contributing to potential sales and margin growth.
Supply ChainLong-term plasma supply agreements have set the stage for achieving over $1 billion in sales by 2030.
Bears Say
Financial PerformanceKey triggers behind the sell-off were a more modest than expected 2025 guide, ambiguity on bullish implications of the enhanced supply agreements, and valuation friction.
RegulatoryADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.
Ownership Overview
3.26% Insiders
21.10% Mutual Funds
14.75% Other Institutional Investors
34.18% Public Companies and Individual Investors
ADMA FAQ
What was ADMA Biologics Inc’s price range in the past 12 months?
ADMA Biologics Inc lowest stock price was $10.07 and its highest was $25.67 in the past 12 months.
What is ADMA Biologics Inc’s market cap?
ADMA Biologics Inc’s market cap is $4.92B.
When is ADMA Biologics Inc’s upcoming earnings report date?
ADMA Biologics Inc’s upcoming earnings report date is Aug 06, 2025 which is in 57 days.
How were ADMA Biologics Inc’s earnings last quarter?
ADMA Biologics Inc released its earnings results on May 07, 2025. The company reported $0.136 earnings per share for the quarter, missing the consensus estimate of $0.153 by -$0.017.
Is ADMA Biologics Inc overvalued?
According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued.
Does ADMA Biologics Inc pay dividends?
ADMA Biologics Inc does not currently pay dividends.
What is ADMA Biologics Inc’s EPS estimate?
ADMA Biologics Inc’s EPS estimate is 0.15.
How many shares outstanding does ADMA Biologics Inc have?
ADMA Biologics Inc has 238,734,250 shares outstanding.
What happened to ADMA Biologics Inc’s price movement after its last earnings report?
ADMA Biologics Inc reported an EPS of $0.136 in its last earnings report, missing expectations of $0.153. Following the earnings report the stock price went down -10.208%.
Which hedge fund is a major shareholder of ADMA Biologics Inc?
Currently, no hedge funds are holding shares in ADMA
ADMA Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.67 (48.81% Upside)
$30.67 (48.81% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $182.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.80%
12-Months-Change
Fundamentals
Return on Equity
78.45%
Trailing 12-Months
Asset Growth
45.51%
Trailing 12-Months
Company Description
ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for ADMA Biologics reflected strong financial growth and operational achievements, notably with the FDA approval for a new production process and raised financial guidance. However, challenges such as voluntary product withdrawals and high operating expenses were also evident. Overall, the sentiment remains optimistic, supported by strategic initiatives and financial strength.Read More>ADMA Stock 12 Month Forecast
Average Price Target
$30.67
▲(48.81%Upside)